benzyloxycarbonyl-Phe-Ala-fluormethylketone,
benzyloxycarbonylphenylalanyl-alanine fluoromethyl ketone,
carbobenzoxy-L-phenylalanyl-(D,L)-alanyl fluoromethyl ketone,
MDL 201053,
MDL 201053, (R-(R*,S*))-isomer,
MDL 201053, (S-(R*,R*))-isomer,
MDL 201117,
MDL-201053,
MDL-201117,
Z-FA-FMK,
Z-Phe-Ala-CH2F,
Z-Phe-Ala-FMK,
Z-Phe-AlaCH2F,
ZFA-fmk,
UNII-1Q2Z3U96CG,
1Q2Z3U96CG,
Z-FA-FMK,
CATHEPSIN B INHIBITOR,
105637-38-5,
Z-Phe-AlaCH2F,
Z-FA-fluoromethyl ketone,
AC1NSK48,
Z-Phe-Ala-fluoromethyl ketone,
Z-Phe-Ala-CH..2..-F,
SCHEMBL9193104,
CHEMBL2402203,
ASXVEBPEZMSPHB-YJBOKZPZSA-N,
197855-65-5,
96922-64-4,
ZINC1547017,
MFCD00883668,
AKOS015910442,
CCG-207881,
CJ-24355,
A14284,
I14-39653,
Z-Phe-Ala fluoromethyl ketone, >=90% (TLC), powder,
UNII-34O3P3306Z component ASXVEBPEZMSPHB-QAPCUYQASA-N,
benzyl N-[(1S)-1-{[(2S)-4-fluoro-3-oxobutan-2-yl]carbamoyl}-2-phenylethyl]carbamate,
benzyl N-[(2S)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate,
Zfa-fmk,
Z-Phe-ala-fmk,
CID5311161,
MDL 201053,
A8170,